---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-018312"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:16:14.630009+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zura Bio appoints Eisner and Nirula to board; Graham resigns

## Summary
- Neil Graham resigned from Zura's board effective Feb 21, 2026; departure not due to any disagreement.
- Mark Eisner (Vir Bio CMO) and Ajay Nirula (Recludix Pharma EVP R&D, former Lilly exec) appointed as directors.
- Each new director receives $40k annual cash retainer and initial option for up to 51,000 shares (or $200k value).
- Board changes come as Zura advances Phase 2 tibulizumab trials in hidradenitis suppurativa and systemic sclerosis.

## SEC filing metadata
- accession: 0001104659-26-018312
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465926018312/0001104659-26-018312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465926018312/tm267035d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-018312
- JSON: https://secwatch.observer/filing/0001104659-26-018312.json
- Plain text: https://secwatch.observer/filing/0001104659-26-018312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.